Minimal residual disease in metastatic breast cancer: Treatment with IFN-β, retinoids, and tamoxifen

Journal of Interferon and Cytokine Research

Volumn 18, Issue 1, 1998, Pages 41-47

  Recchia, Francesco ^a,b,g   Frati, Luigi ^b,c   Rea, Silvio ^b,d   Torchio, Pierfederico ^e   Sica, Gigliola ^f  

^a Ospedale Civile di Avezzano   (Italy)

^b CROFI Monterotondo   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Oncologia Chirurgica Università de L'Aquila   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PREDNISONE; RECOMBINANT BETA INTERFERON; RETINOID; RETINOL PALMITATE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MINIMAL RESIDUAL DISEASE; NAUSEA; PRIORITY JOURNAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING;

EID: 0031930136     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.41     Document Type: Article

References (42)

1. COATES, A., GEBSKI, V., BISHOP, J.F., JEAL, P.N., WOODS, R.L., SNYDER, L., TATTERSAL, M.H.N., BYRNE, M., HARVEY, V., GILL, G., SIMPSON, J., DRUMMOND, R., BROWNE, J., VAN COOTEN, R., and FORBES, J.F. (1987). Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317, 1490-1495.
2. BEZWODA, W.R., SEYMOUR, L., and DANSEY, R.D. (1995). High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J. Clin. Oncol. 13, 2483-2849.
3. THE NORDIC MYELOMA STUDY GROUP. (1996). Interferon-alpha 2B added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. Ann. Intern. Med. 124, 212-222.
4. FRASCI, G., TORTORIELLO, A., FACCHINI, G., CONFORTI, S., CARDONE, A., PERSICO, G., MASTRANTONIO, P., and IAFFAIOLI, R.V. (1993). Intraperitoneal cisplatin-mitoxantrone-interferon-alpha 2B in ovarian cancer patients with minimal residual disease. Gynecol. Oncol. 50, 60-67.
5. GOLDSTEIN, D., BUSHMYERS, S.M., WITT, P.L., JORDAN, V.C., and BORDEN, E.C. (1989). Effect of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res. 49, 2698-2702.
6. DIMITROV, N.V., MEYER, C.J., STRANDER, H., EINHORN, S., and CANTELL, K. (1984). Interferon as a modifier of estrogen receptors. Ann. Clin. Lab. Sci. 14, 32-39.
7. VAN DEN BERG, H.W., LEHAEY. W.J., LYNCH, M., CLARKE, R., and NELSON, J. (1987). Recombinant human interferon alpha increases oestrogen receptor in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effect of tamoxifen. Br. J. Cancer 55, 255-257.
8. SICA, G., NATOLI, V., STELLA, C., and DEL BIANCO, S. (1987). Effect of natural beta interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60, 2419-2423.
9. SICA, G., IACOPINO, F., LAMA, G., AMADORI, D., BARONI, M., LO SARDO, F., MALACARNE, P., MARCHETTI, P., PELLEGRINI, A., ZANIBONI, A., and ROBUSTELLI DELLA CUNA, G. (1993). Steroid receptor enhancement by natural β-interferon in advanced breast cancer. Eur. J. Cancer 29, 329-333.
10. PORZSOLT, F., OTTO, A.M., TRAUSHEL, L.B., BUCK, C., WAWER, A.W., and SCHONENBERGER, H. (1989). Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J. Cancer Res. Clin. Oncol. 115, 465-469.
11. KERR, D.J., PRAGNELL, I.B., SPROUL, A., COWAN, S., MURRAY, T., GEORGE, D., and LEAKE, R. (1989). The cytostatic effects of alpha-interferon may be mediated by transforming growth factor-beta. J. Mol. Endocrinol. 2, 131-136.
12. BUTLER, W.B., and FONTANA, J.A. (1992). Responses to retinoic acid of tamoxifen-sensitive and resistant sublines of human breast cancer cell line MCF-7. Cancer Res. 61, 64-67.
13. CLARKE, C.L., ROMAN, S.D., and GRAHAM, J. (1990). Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. J. Biol. Chem. 265, 12694-12700.
14. GUILBAUD, N.F., GAS, N., DUPONT, M.A., and VALETTE, A. (1990). Effect of differentiation inducing agents on maturation of human MCF-7 breast cancer cells. J. Cell. Physiol. 145, 162-167.
15. MOON, R.C., McCORMICK, D.L., and MEHTA, G.R. (1983). Inhibition of carcinogenesis by retinoids. Cancer Res. 4, 2469-2475.
16. SPORN, M.B., and ROBERTS, A.B. (1983). Role of retinoids in differentiation and carcinogenesis. Cancer Res. 43, 3034-3040.
17. LIPPMAN, S.M., KAVANAGH, J.J., PAREDES ESPINOSA, F., DELGADILLO-MADRUENO, F., PAREDES-CASILLAS, P., HONG, W.K., HOLDENER, E.E., and KRAKOFF, I.H. (1992). 13-cis retinoic acid plus interferon alpha-2A: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst. 84, 241-245.
18. RECCHIA, F., SICA, G., DE FILIPPIS, S., DISCEPOLI, S., REA, S., TORCHIO, P., and FRATI, L. (1995). Interferon-β retinoids and tamoxifen in the treatment of metastatic breast cancer. J. Interferon Cytokine Res. 15, 605-610.
19. KAPLAN, E.L., and MEIER, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
20. COX, D.R. (1972). Regression models and life tables. J.R. Stat. Assoc. 34, 187-202.
21. FINDLER, I.J., and POSTE, G. (1985). The cellular heterogeneity of malignant neoplasms: implication for adjuvant chemotherapy. Semin. Oncol. 12, 207-222.
22. BORDEN, E.C., HOLLAD, H.F., DAO, T.L., GUTTERMAN, J.U., WIENER, L., CHANG, I.C., and PATEL, J. (1982). Leukocyte derived interferon alpha in human breast cancer. Ann. Intern. Med. 97, 1-6.
23. GUTTERMAN, J.U., BLUMENSHEIN, G.R., ALEXANIAN, R., YAP, H.G., BUZDAR, A.U., CABANILLAS, F., HORTBAGYI, G.N., HERSH, E.M., RASSMUSSEN, S.L., MARMON, M., KRAMER, M., and PESTKA, S. (1980). Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann. Intern. Med. 93, 399-106.
24. QUESADA, J.R., HAWKINS, M., HORNING, S., ALEXANIAN, R., BORDEN, E.C., MERIGAN, T., ADAMS, F., and GUTTERMAN, J.U. (1984). Collaborative phase-I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am. J. Med. 77, 427-132.
25. NATHERSELL, A., SMEDLEY, H., KATRAK, M., WHEELER, T., and SIKORA, K. (1984). Recombinant interferon in advanced breast cancer. Br. J. Cancer 49, 615-620.
26. MUSS, H.B., CAPONERA, M., ZECAN, P.G., JACKSON, D.V., Jr., STUART, J.J., and RICHARDS, F. (1985). Recombinant gamma interferon in advanced breast cancer: A phase II trial. Invest. New Drugs 4, 377-381.
27. MUSS, H.B., KEMPF, R.A., MARTINO, S., RUDNICK, S.A., GREINER, G., and COOPER, M.R. (1984). Recombinant alpha interferon in patients with recurrent metastatic breast cancer. J. Clin. Oncol. 2, 1012-1016.
28. SHERWIN, S.A., MAYER, D., OCHS, J.J., ABRAMS, P.G., KNOST, J.A., and FOON, K.A. (1983). Recombinant leukocyte A interferon in advanced breast cancer. Results of phase II efficacy trial. Ann. Intern. Med. 98, 598-602.
29. HAKES, T., MENDEZ-BOTET, C., MOORE, M., and OSBORNE, M. (1990). Modulation of estrogen (ER) and progesterone (PR) receptors in human breast cancer by alpha-2b interferon. Proc. Am. Soc. Clin. Oncol. 9, 44 (abstract).
30. POUILLART, P., PALANGIE, T., JOUVE, M., GARCIA-GILART, E., FRIDMAN, W.H., MAGDELENAT, H., FALCOFF, E., and BILLIAU, A. (1982). Administration of fibroblast interferon to patients with advanced breast cancer: possible effect on skin metastasis and on hormone receptors. Eur. J. Cancer Clin. Oncol. 18, 929-935.
31. BUZZI, F., BRUGIA, M., ROSSI, G., GIUSTINI, L., SCOPONI, C., and SICA, G. (1992). Combination of beta interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res. 12, 869-872.
32. SPORN, M.B. (1991). Future opportunities for clinical use of retinoids and TGF-β. Proc. Ann. Meet. Am. Assoc. Cancer Res. 32, 436.
33. SPORN, M.B., ROBERTS, A.B., WAKEFIELD, L.M., and GLICK, A.B. (1990). Growth factors and retinoids in suppression of neoplasia. Cancer Res. 31, 463-167.
34. MARTH, C., BOCK, G., and DAXENBICHLER, G. (1985). Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. J. Natl. Cancer Inst. 75, 871-875.
35. LIPPMAN, S.M., PARKINSON, D.R., ITRI, L.M., WEBER, R.S., SCHANTS, S.P., and OTA, D.M. (1992). 13-Cis retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl. Cancer Inst. 84, 235-241.
36. LAMA, G., ANGELUCCI, C., RECCHIA, F., and SICA, G. (1996). Effect of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Cancer Lett. 100, 181-189.
37. FONTANA, J.A., COOPER, B.W., BURROWS-MEZU, A.L., and MIRANDA, D. (1990). Retinoid modulation of estradiol stimulated growth and protein synthesis and secretion in human breast carcinoma cells. Cancer Res. 50, 1997-2002.
38. PRABHALA, R.H., GARENVVAL, H.S., HICKS, M.J., SAMPLINER, R.E., and WATSON, R.R. (1991). The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans. Cancer 67, 1556-1560.
39. PASTORINO, U., CHIESA, G., INFANTE, M., SORESI, E., CLERICI, M., VALENTE, M., BELLONI P.A., and RAVASI, G. (1991). Safety of high-dose vitamin A. Randomized trial on lung cancer chemoprevention. Oncology 48, 131-137.
40. CUMMING, F.J., GELMAN, R., and HORTON, J. (1985). Comparison of CAF versus CMFVP in metastatic breast cancer. Analysis of prognostic factors. J. Clin. Oncol. 3, 932-940.
41. LEGHA, S., BENJAMIN, R.S., and MACKAY, B. (1982). Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 96, 133-139.
42. GOLDIE, G.H., COLDMAN, A.J., and GAUDAUSKAS, G.A. (1982). Rationale for the use of alternating non cross resistant chemotherapy. Cancer Treat. Rep. 66, 43-44.